Novartis says biosimilar rituximab accepted for review by FDA
ZURICH (Reuters) – Novartis AG said on Tuesday its biosimilar rituximab to treat blood cancers and immunological diseases such as rheumatoid arthritis was accepted for review by the U.S. Food and Drug Administration (FDA).
Rituximab, made by Novartis’ unit Sandoz, has been proposed as a biosimilar to Roche’s reference medicine Rituxan, Novartis said in a statement.
Rituximab was approved in Europe in June, Novartis said.
Reporting by Silke Koltrowitz